SCHEMBL4865018

SCHEMBL4865018

CCOc1ccc(-c2cc(NN=C3C(=O)NN=C3c3cc(OC)ccc3OC)ccc2C)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.38
KMT2A Q03164 8/20 0.37
MAPT P10636 7/20 0.37
NPSR1 Q6W5P4 2/20 0.37
MEN1 O00255 6/20 0.37
LMNA P02545 6/20 0.37
ALDH1A1 P00352 4/20 0.37
MAPK1 P28482 4/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
HTT P42858 2/20 0.36
RAB9A P51151 2/20 0.36
TP53 P04637 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
TSHR P16473 3/20 0.34
GAA P10253 2/20 0.34
KDM4E B2RXH2 1/20 0.34
SYK P43405 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4866929 0.90 GAA (0.36) SMN1; SMN2KMT2AMAPTMEN1LMNA
SCHEMBL4866935 0.90 GAA (0.36) SMN1; SMN2KMT2AMAPTMEN1LMNA
SCHEMBL4859338 0.88 MEN1 (0.38) SMN1; SMN2KMT2AMAPTMEN1LMNA
SCHEMBL4863110 0.88 TUBB4A (0.42) SMN1; SMN2KMT2AMAPTNPSR1MEN1
SCHEMBL4863104 0.88 TUBB4A (0.42) SMN1; SMN2KMT2AMAPTNPSR1MEN1
SCHEMBL4859340 0.88 MEN1 (0.38) SMN1; SMN2KMT2AMAPTMEN1LMNA
SCHEMBL4857883 0.87 TUBB4A (0.37) SMN1; SMN2KMT2AMAPTNPSR1MEN1
SCHEMBL4867109 0.84 CYP11B1 (0.42) KMT2ANPSR1MEN1ALDH1A1L3MBTL1
SCHEMBL4867111 0.84 CYP11B1 (0.42) KMT2ANPSR1MEN1ALDH1A1L3MBTL1
SCHEMBL4865279 0.83 MEN1 (0.36) SMN1; SMN2KMT2AMAPTMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7452873-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-18 US disclosed
US-20050222237-A1 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2005-10-06 US disclosed
US-6916798-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-07-12 US disclosed
US-20040024040-A1 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024040-A1 Inhibitors of GSK-3 and uses thereof GSK3B, AURKC, GSK3A SMN1; SMN2 2612/4885KMT2A 688/4885MAPT 154/4885
US-20050222237-A1 Inhibitors of GSK-3 and uses thereof GSK3B, AURKC, GSK3A SMN1; SMN2 2612/4885KMT2A 688/4885MAPT 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.